다중 암 조기 발견(MCED) 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Global Multi Cancer Early Detection Market was valued at USD 1015.05 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.10% through 2030. The global multi-cancer early detection market has witnessed remarkable growth in recent years, driven by advancements in technology, increased awareness, and a growing emphasis on preventive healthcare. Early detection of cancer can significantly improve patient outcomes, making it a critical area of focus in the healthcare industry. Cancer remains one of the leading causes of death worldwide, with millions of lives lost each year. Early detection plays a pivotal role in improving the survival rates of cancer patients, as it enables timely interventions and personalized treatment plans. The global multi-cancer early detection market encompasses a wide range of diagnostic tools and technologies designed to identify various types of cancer at the earliest stages. Liquid biopsy has gained prominence as a minimally invasive method for detecting cancer biomarkers in bodily fluids. It offers the potential for early cancer detection without the need for invasive procedures. AI and machine learning algorithms are being used to analyze vast amounts of patient data, making it possible to identify cancer-related patterns and markers with higher precision. Integrating multiple 'omics' data, such as genomics, proteomics, and metabolomics, is enabling a more comprehensive understanding of cancer and early detection. Governments and healthcare organizations worldwide are increasingly investing in cancer screening programs to reach a broader population and detect cancer at earlier stages. The global multi-cancer early detection market is poised for significant growth in the coming years. Advances in technology, increased investment in research and development, and the integration of AI and big data analytics are expected to drive innovation and improve the accuracy of cancer detection methods. Also, the growing awareness of the importance of early cancer detection among patients and healthcare providers will contribute to market expansion. Governments and healthcare organizations are likely to continue supporting initiatives aimed at improving cancer screening and early detection programs.

Key Market Drivers

Rising Cancer Incidence Rates

The rising global incidence of cancer is one of the most significant drivers of the Multi-Cancer Early Detection (MCED) market. As cancer rates continue to surge, the demand for advanced, non-invasive, and early detection solutions has grown exponentially. This increasing burden presents both a critical healthcare challenge and a substantial business opportunity for MCED companies. Cancer is now the second leading cause of death worldwide, and its incidence is projected to grow due to multiple factors, including aging populations, lifestyle changes, and environmental risks. By 2050, global cancer cases are projected to rise to over 35 million, marking a 77% increase from the 20 million cases estimated in 2022. This escalating burden is driven by a combination of factors, including population aging, demographic growth, and shifting exposure to risk factors, many of which are linked to socioeconomic development. Traditional cancer screening methods focus only on specific cancer types (e.g., mammograms for breast cancer, colonoscopy for colorectal cancer), often leading to late-stage diagnoses for other cancers that lack routine screening programs. MCED tests offer a transformative solution by detecting multiple cancers through a single blood test, significantly improving early diagnosis rates and reducing cancer-related mortality. This urgent medical need is pushing healthcare systems and governments to adopt comprehensive early detection strategies, creating a favorable market environment for MCED solutions.

Key Market Challenges

Sensitivity and Specificity

One of the most significant challenges in multi-cancer early detection is achieving high sensitivity and specificity in diagnostic tests. Many existing tests may produce false positives or miss early-stage cancers, leading to unnecessary anxiety for patients or delayed diagnoses. Developing highly accurate tests that can reliably distinguish between cancer and non-cancer conditions remains a formidable challenge.

Key Market Trends

Technological Advancements

In recent years, technological advancements in the field of healthcare have been nothing short of revolutionary. These advancements are not only improving the way diseases are diagnosed and treated but are also making it possible to detect and combat diseases at their earliest stages. One of the most significant areas benefiting from these innovations is the global multi-cancer early detection market. As technology continues to evolve, it is driving the expansion of this market, offering new hope for early cancer detection, diagnosis, and ultimately, improved patient outcomes. Liquid biopsies have emerged as a game-changer in the early detection of cancer. These blood tests can detect fragments of DNA or other molecules released by cancer cells, allowing for the identification of cancer at an earlier stage than traditional methods. The development of highly sensitive and specific liquid biopsy tests is driving the growth of multi-cancer early detection. Machine learning and AI algorithms have proven invaluable in analyzing vast amounts of medical data quickly and accurately. AI-powered tools can identify subtle patterns and anomalies in medical images and patient records, aiding in the early detection and diagnosis of cancer. This technology is making it possible to process information at a scale that was previously unattainable. Next-Generation Sequencing (NGS) technology has revolutionized genomic analysis and is now being used extensively in cancer research. It allows for the comprehensive analysis of an individual's DNA, helping to identify genetic mutations associated with cancer. This information can be used for early detection and personalized treatment plans.

Key Market Players

• Grail, LLC
• Exact Sciences Corporation.
• Foundation Medicine, Inc.
• AnchorDx Medical Co Ltd
• Guardant Health, Inc.
• Burning Rock Biotech Limited
• genecast biotechnology co. ltd
• Laboratory for Advanced Medicine, Inc.
• Singlera Genomics Inc.

Report Scope:

In this report, the Global Multi Cancer Early Detection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multi Cancer Early Detection Market, By Type:

• Liquid Biopsy
• Gene Panel
• LDT
• Others

Multi Cancer Early Detection Market, By End User:

• Hospitals
• Diagnostic Laboratories
• Others

Multi Cancer Early Detection Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multi Cancer Early Detection Market.

Available Customizations:

Global Multi Cancer Early Detection market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Multi Cancer Early Detection Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Liquid Biopsy, Gene Panel, LDT & Others)
  • 5.2.2. By End-user (Hospitals, Diagnostic Laboratories, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Multi Cancer Early Detection Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By End-user
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multi Cancer Early Detection Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By End-user
  • 6.3.2. Canada Multi Cancer Early Detection Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By End-user
  • 6.3.3. Mexico Multi Cancer Early Detection Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By End-user

7. Europe Multi Cancer Early Detection Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By End-user
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Multi Cancer Early Detection Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By End-user
  • 7.3.2. United Kingdom Multi Cancer Early Detection Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
  • 7.3.3. Italy Multi Cancer Early Detection Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By End-user
  • 7.3.4. France Multi Cancer Early Detection Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By End-user
  • 7.3.5. Spain Multi Cancer Early Detection Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By End-user

8. Asia-Pacific Multi Cancer Early Detection Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End-user
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multi Cancer Early Detection Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End-user
  • 8.3.2. India Multi Cancer Early Detection Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End-user
  • 8.3.3. Japan Multi Cancer Early Detection Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End-user
  • 8.3.4. South Korea Multi Cancer Early Detection Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By End-user
  • 8.3.5. Australia Multi Cancer Early Detection Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By End-user

9. South America Multi Cancer Early Detection Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End-user
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multi Cancer Early Detection Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End-user
  • 9.3.2. Argentina Multi Cancer Early Detection Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End-user
  • 9.3.3. Colombia Multi Cancer Early Detection Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End-user

10. Middle East and Africa Multi Cancer Early Detection Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By End-user
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multi Cancer Early Detection Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By End-user
  • 10.3.2. Saudi Arabia Multi Cancer Early Detection Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By End-user
  • 10.3.3. UAE Multi Cancer Early Detection Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Type Development
• 12.3. Recent Developments

13. Global Multi Cancer Early Detection Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Grail, LLC
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Exact Sciences Corporation.
• 14.3. Foundation Medicine, Inc.
• 14.4. AnchorDx Medical Co Ltd
• 14.5. Guardant Health, Inc.
• 14.6. Burning Rock Biotech Limited
• 14.7. genecast biotechnology co. ltd
• 14.8. Laboratory for Advanced Medicine, Inc.
• 14.9. Singlera Genomics Inc

15. Strategic Recommendations

16. About Us & Disclaimer